Article
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
BMC cancer - 10 Jan 2014
Ihle Michaela Angelika, Fassunke Jana, König Katharina, Grünewald Inga, Schlaak Max, Kreuzberg Nicole, Tietze Lothar, Schildhaus Hans-Ulrich, Büttner Reinhard, Merkelbach-Bruse Sabine
Abstract excerpt
BACKGROUND: The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 (p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or par...
Topics
- Antineoplastic Agents
- Biomarkers, Tumor
- DNA Mutational Analysis
- High-Throughput Nucleotide Sequencing
- Humans
- Immunohistochemistry
- Indoles
- Melanoma
- Molecular Targeted Therapy
- Mutation
- Paraffin Embedding
- Patient Selection
- Polymerase Chain Reaction